Entera Bio Ltd. has recently filed a $100 million mixed securities shelf registration statement with the U.S. Securities and Exchange Commission (SEC). This filing allows the company to offer and sell various securities, including ordinary and preferred shares, debt securities, warrants, and units, providing the flexibility to raise capital as needed over time.
In a related development, Entera Bio completed a private placement in December 2023, where it issued approximately 7.9 million units at $0.835 per unit. This effort raised about $6.6 million, and as of June 30, 2024, the company reported having $9.1 million in cash and cash equivalents. Reuters reported that this capital is expected to support their operations into the third quarter of 2025, covering a range of expenses such as regulatory and research costs.
The newly filed registration aligns with Entera Bio's broader strategic goals. The company intends to use potential future offering proceeds for general working capital, clinical trials, and regulatory activities, ensuring its financial stability and supporting ongoing corporate initiatives. This move also highlights the company's commitment to regulatory compliance and transparency in its financial operations.